endp broke 52 week low on high volume but as of yesterday ENDP announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had voted in the ratio of 18 to eight and consented that the benefits of reformulated Opana ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. Which could be seen as good news for investors since the drugs wont be taken off market although there is still tough generic competition